Xsolla Unveils COPPA and GDPR-K Certified Parental Controls, Enabling Developers to Implement Compliant Direct-to-Consumer Strategies
23.10.2024 15:00:00 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, is proud to introduce its Parental Controls solution, now certified with the Children's Online Privacy Protection Rule (COPPA) and GDPR-K badges. Xsolla’s enhanced Parental Controls offer game developers an integrated solution to safeguard young gamers while enabling parents to manage and control their children's access to digital payments, ensuring secure transactions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241023685423/en/
(Graphic: Xsolla)
As developers begin to embrace direct-to-consumer strategies, such as web shops, to complement platform sales, they face new challenges around compliance. While platforms manage many regulatory issues, games sold directly to consumers must navigate complexities that platforms previously shielded them from. This has become especially critical in recent years, as the Federal Trade Commission (FTC) has taken action against several game developers and digital content providers for violations of the Children's Online Privacy Protection Act (COPPA).
Adhering to legal standards like COPPA and GDPR to fulfill jurisdictional requirements in every market highlights the rising demand for effective parental control solutions. In response to the growing demand—especially on platforms where younger players are more vulnerable to excessive spending—Xsolla, following its partnership with PRIVO just last year, has developed a robust suite of Parental Control tools.
Xsolla Parental Controls key features include:
- Age Gating: Accurately verify users' ages to ensure compliance with regulations and protect minors from unauthorized transactions.
- Guardian Consent & Real-Time Notifications and Approval: Allow guardians to receive instant email or SMS notifications to approve or reject transactions initiated by minors, providing an additional layer of security and control.
- Comprehensive Transaction History: This option displays all transactions in the guardian’s Xsolla account, offering complete transparency and ease of monitoring.
- Spending Limits: Enable guardians to set specific spending limits and permissions for minors, tailoring the experience to fit their family’s needs.
Anton Zelenin, Chief Product Officer, Fintech at Xsolla, shared his thoughts on the release: “At Xsolla, we believe that creating a safe and secure environment for young gamers is essential. Our COPPA-certified Parental Controls empower parents and developers by ensuring transparency and safety in gaming transactions. We are committed to helping developers meet regulatory requirements while providing peace of mind to families.”
Xsolla Parental Controls solution empowers game developers to comply with global regulations while giving parents enhanced visibility and control over in-game transactions. By integrating this feature, Xsolla addresses critical concerns about protecting children from unauthorized or excessive purchases, fostering a safer gaming environment for families worldwide.
For more information about Xsolla’s Parental Controls and how they can enhance payment security and compliance in your games, visit Xsolla | Xsolla Blog
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world, Xsolla supports leading gaming partners such as Valve, Twitch, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, among others.
For additional information and to learn more, please visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023685423/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom